Oddity Tech Earnings Call Transcripts
Fiscal Year 2026
-
Q3 revenue and adjusted EBITDA beat guidance as SpoiledChild and METHODIQ grew, while IL MAKIAGE’s ad-account disruption persisted. FY 2026 guidance increased, and 2027 plans center on returning to growth through brand and peptide launches.
-
Net revenue declined 25% year-over-year due to IL MAKIAGE's ad algorithm issue, but SpoiledChild and METHODIQ showed strong growth and high repeat rates. The company expects sequential improvement, with Q3 revenue down ~5% and full-year revenue down ~19%.
-
Q1 2026 net revenue declined 26% year-over-year due to a technical issue with the largest ad partner, causing high CPA and reduced new customer acquisition. Remediation efforts are showing early signs of improvement, and full-year adjusted EBITDA is expected to be positive.
Fiscal Year 2025
-
Delivered record 2025 results with 25% revenue growth and strong repeat sales, but faces a temporary setback in 2026 due to sharply higher user acquisition costs from ad platform algorithm changes. Remediation is underway, with normalization expected in H2.
-
Q3 saw 24% revenue and adjusted EPS growth, exceeding guidance, driven by strong online sales and international expansion. METHODIQ, a new telehealth dermatology brand, launched with a major media push. Full-year guidance was raised, with robust cash reserves and continued investment in innovation.
-
The company leads the direct-to-consumer beauty sector with strong online growth, high repeat sales, and a robust innovation pipeline. New brands, international expansion, and proprietary R&D drive future growth, while disciplined capital allocation and margin targets remain central.
-
The company’s agile, tech-driven direct-to-consumer model supports strong growth, with multiple brands scaling rapidly and international expansion set for 2025. Innovation through ODDITY Labs and disciplined capital allocation underpin a long-term goal of 20% annual revenue growth and high profitability.
-
Revenue grew 26% year-over-year in H1 2025, with strong Q2 results and robust free cash flow. Guidance for 2025 was raised, with new brand launches and international expansion driving future growth. Brand 3's Q4 launch targets the medical-grade dermatology market.
-
Q1 2025 delivered 27% revenue growth and record profitability, prompting raised full-year guidance. D2C and international expansion, new brand launches, and tech investments drive momentum, with strong cash flow and limited tariff risk supporting future growth.
Fiscal Year 2024
-
Revenue grew 27% in 2024 to $647M, with adjusted EBITDA up 40% and strong free cash flow. Both Il Makiage and SpoiledChild delivered double-digit growth, and repeat sales exceeded 60% of revenue. 2025 guidance targets 20% revenue growth and 20% EBITDA margin, with Brand 3 launching in H2.
-
A leading online beauty platform leverages technology, data, and proprietary innovation to drive growth, aiming for billion-dollar brands and global expansion. Strong repeat business, high margins, and a robust balance sheet support its strategy, with AI and vision tools enhancing customer experience and product development.
-
-
Q3 saw 26% revenue growth and record profitability, driven by strong repeat business and technology investments. Guidance for 2024 was raised, with continued margin strength and robust cash flow, while new brands and labs are set to drive future growth.
-
Record Q2 and H1 2024 with 28% revenue growth, strong margins, and high repeat sales. Raised full-year guidance, continued investment in new brands and science, and announced a new Chief Science Officer. No signs of consumer weakness; share buybacks ongoing.